Centrient Pharmaceuticals* opens Barcelona Innovation Laboratory to accelerate product and process development

• Centrient’s first dedicated Innovation Laboratory is a strategic step that will support product diversification and drive further development of sustainable and efficient manufacturing processes.
• The laboratory is located at Almirall’s R&D centre, supporting Almirall’s ambition to create a hub for scientific collaboration and open innovation.

Rotterdam, the Netherlands & Barcelona, Spain – Centrient, the leading business-to-business manufacturer of life-saving, foundational medicines to the global healthcare system, today opens a new dedicated innovation lab at Almirall S.A.’s (BME: ALM) Research & Development (R&D) centre in Sant Feliu de Llobregat in the province of Barcelona, Spain.

The opening of the new laboratory, which will focus on both product and process development, builds on Centrient's track record of pioneering sustainable practices in pharmaceutical manufacturing. The laboratory will enable the company to develop a more diversified and innovative portfolio with a focus on the sustainable development of new products and production practices, a key element of Centrient's strategic roadmap to 2030. Furthermore, it will enable Centrient to leverage its manufacturing capabilities and process development acumen to become a key contributor to open innovation in the global pharmaceutical value chain. This addition will accelerate Centrient's strategic evolution from manufacturer to innovation partner in the markets it serves, providing value-added products that meet the needs of customers, patients and other Centrient stakeholders worldwide.

The Centrient Innovation Laboratory is part of the existing R&D centre in Sant Feliu de Llobregat operated by Almirall, a global biopharmaceutical company specialising in medical dermatology. The centre aims to be a hub where researchers from biotech companies, start-ups, universities, and other scientific institutions can collaborate. This creative scientific space is expected to create opportunities for open innovation between Centrient and Almirall colleagues, as well as future partners. Barcelona is an attractive hub for attracting talent and Centrient has created more than 100 roles.

Rex Clements, Chief Executive Officer of Centrient: “The opening of this new Innovation Laboratory marks an important milestone in our history. It will be the focal point for product and process innovation at Centrient as we continue to diversify our portfolio and develop our biotechnology capabilities. The steps we are taking will ensure that we are better prepared for an ever-changing industry landscape, and well positioned in our transition from a manufacturer to an innovation partner for our markets.”

Jorge Gil-Martinez, Chief Scientific Officer of Centrient Pharmaceuticals: “This collaboration represents a huge step in our journey towards an Open Innovation model, where we aim to create synergies with strategic partners to accelerate our mission: enable state-of-the- art innovative processes for our products and a diversified portfolio.”

About Centrient Pharmaceuticals
Headquartered in Europe, Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing.

For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.

*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.